Casma Therapeutics is harnessing the power of autophagy to bring cures to patients with serious diseases. The traditional pharma approach is to use drugs to inhibit the active site of a disease-causing protein. An alternative strategy is to instead destroy the protein entirely. Autophagy is a major cellular degradation pathway that recycles damaged components. Casma’s approach is to boost autophagy and degradation by developing drugs against unique molecular targets generated from their platform.
Initially Casma is focusing on new treatments for patients with unmet clinical needs including rare genetic diseases and broader areas such as neurodegeneration, metabolic disorders, and muscle degeneration.